BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030
1. BioMarin's Q2 earnings of $1.44 beat consensus by 59%. 2. Voxzogo revenue grew 20% year-over-year, driving strong sales. 3. 2025 earnings guidance raised to $4.40-$4.55 per share. 4. BMN 333 shows promising Phase 1 data, but revenue expected by 2030. 5. Competition for Palynziq in 2025 could affect revenue growth.